Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
  • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
  • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
  • A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
  • A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
  • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
  • A61M5/142—Pressure infusion, e.g. using pumps
  • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
  • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • G—PHYSICS
  • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
  • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
  • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
  • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• • G—PHYSICS
  • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
  • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
  • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
  • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
  • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• • G—PHYSICS
  • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
  • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
  • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
  • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Definitions

• Type 1 Diabetes Mellitus is a metabolic autoimmune disease characterized by the destruction of the pancreas' beta cells, and results in the body being incapable of producing insulin, a hormone that serves at least two important functions. The first is to facilitate the absorption of glucose from the blood-stream into many types of cell. The second function is to participate, in conjunction with glucagon (insulin's antagonist), in the endocrine feedback loop that regulates the liver' s release/removal of glucose into/from the blood-stream.
• glucagon insulin's antagonist
• hypoglycemia has very near-term consequences and may result in, e.g., dizziness or disorientation if mild, fits or unconsciousness if serious, and irreversible coma or death in severe cases.
• a hyperglycemic state has few consequences if it is brief.
• a blood-glucose level that is high on average over long periods of time may result in a plethora of health problems, e.g., cardiovascular disease, kidney failure and retinal damage, possibly many years down the line.
• the overall goal of this work is an artificial pancreas for the automated delivery of insulin to people with T1DM [1,2,3].
• a crucial element of any fully automated artificial pancreas is a feedback control law that performs algorithmic insulin dosing that is effective and safe.
• a variety of such glycemia controllers have been proposed, e.g., based on Model Predictive Control (MPC) [4,5,6,7], proportional-integral-derivative control [8,9], and adaptive neural networks [10].
• MPC Model Predictive Control
• One advantage of MPC is the large degree of flexibility in formulating the control objective, and this flexibility was exploited in our development of glycemia controllers based on zone-MPC [5,6,11], whereby the blood-glucose levels are
• the invention provides a zone-MPC law that strategically reduces the risk of hypoglycemia during the night - assumed to be the time of sleep.
• One innovation over the time-invariant zone-MPC strategy of [5,6,11] is that the invention is periodically time dependent w.r.t. the time of day. Specifically, during the night the blood-glucose target zone is raised, and the bound on the maximum insulin infusion rate is reduced, from the values employed during the day. The motivation for the former is to induce a rise of blood-glucose levels at night. The latter is enforced as a further safety mechanism and reduces the chance of controller induced hypoglycemia.
• the key component in a successful artificial pancreas system designed to maintain the blood glucose concentrations of people with type 1 diabetes mellitus within the euglycemic zone (80-140mg/dL) is the control algorithm, which automatically directs the delivery of insulin to be administered to a subject with type 1 diabetes.
• the controller must meet a variety of challenges, such as the inherent long time delays between subcutaneous sensing,
• the present invention facilitates the testing and verification of glycemia controllers over prolonged, multi-day periods of time.
• the disclosed controllers achieve this safely by continuously modulating their control objective depending on the time of day.
• the target blood glucose zone values during the night are higher than during the day, and there is a period of smooth transition between the daytime and nighttime.
• the insulin input constraints enforced by the controller are lower during the night than during the day.
• the invention provides a controller for an artificial pancreas for automated insulin delivery to patients with type 1 diabetes mellitus (TIDM) that enforces safe insulin delivery throughout both day and night, wherein the controller employs zone model predictive control, whereby real-time optimization, based on a model of a human's insulin response, is utilized to regulate blood glucose levels to a safe zone, and time-dependent zones that smoothly modulate the controller correction based on the time of day, wherein the controller strategically strives to maintain an 80-140 mg/dL glucose zone during the day, a 110-220 mg/dL zone at night, and a smooth transition of 2 hour duration in between.
• TIDM type 1 diabetes mellitus
• the invention provides a controller for an artificial pancreas that automatically directs the delivery of insulin to maintain blood glucose concentrations of people with type 1 diabetes mellitus (TIDM) within the euglycemic zone (80-140mg/dL) using a control algorithm that continuously modulates the control objective depending on the time of day, wherein target blood glucose zone values during the night are higher than during the day, there is a period of smooth transition between the daytime and nighttime, and insulin input constraints enforced by the controller are lower during the night than during the day, wherein elevated blood glucose levels are permitted during the night, and the maximum amount of insulin deliverable by the artificial pancreas device while the patient is asleep is reduced, and risk of controller induced hypoglycemia during periods of sleep is thus reduced.
• TIDM type 1 diabetes mellitus
• the invention provides a periodic zone model predictive control (PZMPC) controller adapted for directing insulin, particularly from an artificial pancreas.
• PZMPC periodic zone model predictive control
• the invention also provides corresponding algorithms for programming the subject controllers to effectively implement the disclosed control steps.
• the invention also provides an artificial pancreas system or subsystem comprising a subject controller, which may comprise for example, the controller and a pump (e.g.
• the invention also provides a periodic zone model predictive control (PZMPC) scheme of an artificial pancreas (AP) for Type 1 diabetes applications comprising a control algorithm which directs a subject controller.
• PZMPC periodic zone model predictive control
• the invention also provides a method comprising directing and optionally, delivering, insulin delivery using a subject controller.
• the invention includes controllers, algorithms and insulin directing systems essentially as described herein, and all combinations of the recited particular embodiments. All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.
• Fig. Daily periodic blood-glucose target zone boundaries.
• Fig. 5 Blood-glucose mean trajectories and min-max envelopes.
• Fig. 6 CVGA plot for 100 in silico subjects and PZMPC.
• Fig. S Process flow diagram of the real-time control protocol.
• the invention provides an artificial pancreas for automated insulin delivery to patients with type 1 diabetes mellitus (T1DM).
• T1DM type 1 diabetes mellitus
• 4 UC2013-384PCT artificial pancreas is a strategy to perform safe and effective insulin dosing, and we have successfully developed control algorithms that achieve this task. Rigorous testing requires first to operate controllers for multi-day periods, and second to move trials from clinics to an outpatient environment.
• the invention provides a fully automatic control strategy that enforces safe insulin delivery throughout both day and night.
• the control strategy employs zone model predictive control, whereby real-time optimization, based on a model of a human' s insulin response, is utilized to regulate blood glucose levels to a safe zone.
• zone model predictive control whereby real-time optimization, based on a model of a human' s insulin response, is utilized to regulate blood glucose levels to a safe zone.
• One inventive aspect of our solution is the use of time- dependent zones that smoothly modulate the controller correction based on the time of day. Specifically, the controller strategically strives to maintain an 80-140 mg/dL glucose zone during the day, a 110-220 mg/dL zone at night, and a smooth transition of 2 hour duration in between.
• the subject controller Based on a test of 10 in silico adult subjects on a typical meal schedule, the subject controller administers on average 7.0% and 2.2% less insulin during the night than current fixed-zone controllers and basal-bolus therapy, respectively, and thereby alleviates the risk of nocturnal hypoglycemia. Furthermore, the controller produces excellent responses to unannounced meals, severe hyperglycemia and unannounced, self-administered insulin boluses.
• the subject control strategy is a significant step towards safe and continuous evaluation of artificial pancreases on people with T1DM in an outpatient environment for prolonged periods of time.
• PZMPC Periodic-Zone Model Predictive Control
• control input u is required to satisfy
• p E N + denote a finite period length (i.e., corresponding to 24h for diurnal periodicity).
• zone-excursion function Z RxRxR— R : .
• Problem 2 can be formulated as a quadratic program that is convex, although generally not strictly convex.
• a state-estimate is required to initialization the predicted state trajectory in (4).
• a Luenberger-observer is employed (see, e.g., [14]).
• the state-estimator is based on the same plant model (1) employed for prediction in Problem 2 and is implemented as
• the SISO LTI model of [5] is employed, summarized as follows.
• the scalar plant input is the administered insulin rate ⁇ [U/h]
• the scalar plant output is the subject's blood-glucose value >3 ⁇ 4G [mg/dL].
• Let the scalar input and output of LTI model (1) be defined respectively as:
• T s 5 [min] sample-period.
• Z 1 denote the backwards shift operator.
• the transfer characteristics from u to y are described by
• the target zone is both elevated and wider during the night than during the day.
• the elevated lower bound implies that the controller reduces the insulin input rate to below the basal rate at higher blood-glucose values during the night than during the day.
• the highly elevated upper bound implies that the controller administers an insulin input rate exceeding the basal rate only at blood-glucose levels that are high enough to pose a serious and near-term health risk. It furthermore implies that during the night the controller makes no attempt to lower any blood- glucose level less than 220 [mg/dL], even though a level of 220 [mg/dL] would pose a considerable health risk if maintained indefinitely. This trade-off appears, at present, to be necessary in order to reduce the likelihood of immediately life-threatening nocturnal hypoglycemic events.
• the daytime zone is employed from 7am to 10pm, the nighttime zone from 12pm to 5am, and there are two two-hour periods in between where the controller smoothly transitions the target zone bounds based on a cosine function.
• the target zone bounds are plotted over the course of one day in Fig. 1.
• the transition function is omitted as straightforward.
• the disclosed MPC strategy enforces daily periodically time-dependent, hard, insulin input rate constraints via (2).
• the input rate is bounded from above only by the pump's maximum achievable flow-rate, and is thus hardware dependent. Note that this maximum rate is unlikely to ever be commanded by the controller.
• the input rate is limited from above to 1.5x the subject's basal rate (see Section III-D), and is subject-specific.
• the insulin input rate's lower bound is zero at all times. Daytime is from 5am to 10pm. All other times are nighttime - there is no transition period. Note that the start of day- and nighttimes coincides with the start of the output zones' transition periods. The insulin bounds are plotted over the course of one day in Fig. 2.
• the disclosed PZMPC strategy is tested using the Uni. Padova/UVa FDA accepted metabolic simulator [15] with 100 in silico adult subjects.
• the PZMPC strategy is compared to two alternative control strategies.
• the first alternative is the zone-MPC strategy described in [5,6] employing the same blood-glucose target zone (equal to the PZMPC daytime zone) at all times of day. This strategy is referred to here as invariant-zone MPC.
• the second alternative employs the invariant-zone MPC strategy only during the day (5am-10pm), and delivers the subject- specific basal insulin input rate during the night (10pm-5am). This strategy is referred to as the nighttime-basal strategy.
• the purpose of the experiment is to demonstrate increased safety margins during the night when using the disclosed PZMPC algorithm.
• the simulations start at 1pm and end at 6pm the following day (simulated time).
• the controllers operate in closed- loop from 4pm on the first day until the end of the simulation.
• a 50g dinner, 40g breakfast and 15g snack is provided at 6pm, 7am (next day) and 2pm (next day), respectively.
• Meal weights refer to carbohydrates. Results prior to 6pm on the first day are ignored to reduce the effects of initial conditions.
• the simulation result for an in silico subject that displays very typical behavior is depicted in Fig. 3.
• the main response difference, as desired and expected, is an elevated blood-glucose level during the night when using PZMPC. This is achieved by imposing a prolonged reduction in insulin input rate during the transition from daytime zone to nighttime zone starting at about 10pm.
• the three control strategies produce the same output response
• FIG. 5 Plotted in Fig. 5 are the trajectories of mean blood-glucose values over all 100 in silico subjects.
• the three control strategies produce very similar mean responses until midnight and after 9am, with the PZMPC, invariant-zone MPC and nighttime-basal strategies producing successively lower mean glucose responses during the night and early morning.
• Fig. 5 Also plotted in Fig. 5 are the min-max envelopes of the blood-glucose responses for the three contrasted control strategies. Again, before midnight and after about 9am the envelopes are very similar. However, the PZMPC, invariant-zone MPC and nighttime-basal strategies result in significantly different nighttime envelope boundaries. Of particular interest for the purpose of increased safety margins is that with the PZMPC approach the nighttime lower-bound of the envelope spends much time near (partly above) 100 mg/dL.
• the ratio of mean blood-glucose level achieved with invariant-zone MPC vs. the mean blood-glucose level achieved with PZMPC is less than unity for each in silico subject, both for the whole day and only nighttime.
• the ratio of total insulin delivery with invariant- zone MPC vs. the total insulin delivery with PZMPC is greater than unity for each in silico subject during the night, and greater than unity for all except one in silico subject for the whole day. The one exception is described in more detail in Section IV-D.
• the behavior is a statistical exception, but not surprising, and conforms to the response that can be expected from the PZMPC controller.
• One of the purposes of the Uni. Padova/UVa simulator is to facilitate the testing of glycemia controllers on virtual patients that have physiological parameters over a wide spectrum.
• An MPC strategy employing daily periodic blood-glucose target zones and daily periodic insulin input constraints is provided to safely operate glycemia controllers for prolonged, multi-day periods, including times that the subject is asleep.
• This control strategy is useful for the testing, verification and operation of an artificial pancreas for the treatment of TIDM.
• silico testing confirmed that the strategy achieves the goal of reducing the threat of hypoglycemia during nighttime.
• More advanced periodic MPC schemes are also provided; for example, the inclusion of diurnal physiological time-dependence in the insulin-glucose dynamics, and the incorporation of time-dependent changes in subject behavior over a typical week.
• Fig. 1 Daily periodic blood-glucose (JBG) target zone boundaries [mg/dF]. Daytime: 7am-10pm. Nighttime: 12pm-5am. Daytime zone: [80; 140] mg/dF. Nighttime zone: [110; 220] mg/dF. Smooth transition of two hour duration (5-7am, 10-12pm) based on cosine function.
• JBG blood-glucose
• Fig. 2 Daily periodic constraints on the insulin input rate uw [U/h]. Daytime: 5am- 10pm. Nighttime: 10pm-5am. Daytime upper-bound is pump-maximum: Hardware dependent. Nighttime upper-bound is 1:5 Wbasai : Subject-specific. Fower-bound is 0 [U/h] at all times.
• FIG. 3 Simulation result.
• Top plot is blood-glucose [mg/dF]: PZMPC (blue, solid), invariant- zone MPC (red, dashed), nighttime-basal (black, dash-dotted).
• Fower three plots are insulin input rate [U/h]: PZMPC (blue, top), invariant- zone MPC (red, middle), nighttime- basal (black, bottom). This in silico subject results in trajectories with typical characteristics.
• FIG. 4 Simulation result.
• Top plot is blood-glucose [mg/dF]: PZMPC (blue, solid), invariant- zone MPC (red, dashed), nighttime-basal (black, dash-dotted).
• Fower three plots are insulin input rate [U/h]: PZMPC (blue, top), invariant- zone MPC (red, middle), nighttime- basal (black, bottom). This in silico subject resulted in atypically large deviations between the contrasted control laws.
• PZMPC resulted in more total insulin delivery than invariant- zone MPC and nighttime-basal strategies.
• Fig. 5 Blood-glucose (JBG [mg/dF]) mean trajectories and min-max envelopes over 100 in silico subjects. Mean trajectories identical on each subplot: PZMPC (blue, solid), invariant- zone MPC (red, dashed), nighttime-basal (black, dash-dotted). Envelopes: PZMPC (top), invariant-zone MPC (middle), nighttime-basal (bottom).
• Fig. 6 CVGA plot for 100 in silico subjects and PZMPC (see also Table II).
• Zone MPC glycemia controllers in fully closed- loop mode for extended, multi-day periods of time.
• Operating glycemia controllers for extended periods of time is indispensable for the development, testing and verification of an artificial pancreas that is fully automated and requires no specialist supervision.
• the control strategy employed is a feedback-control strategy, where measurements of blood glucose values are used by the controller in order to determine a value of the insulin
• the control algorithm is a so-called Model Predictive Control (MPC) algorithm.
• MPC employs an explicit model of the process to be controlled when optimizing the input.
• MPC controllers for glycemia control use a model of a human's T1DM glucose- insulin dynamics to predict the evolution of the blood glucose values over a so-called prediction horizon of P controller steps, and optimize a predicted insulin input trajectory in order to optimize a specified cost objective that penalizes unsafe glycemic values and also insulin usage.
• the MPC controller determines an optimal predicted insulin input trajectory into the future. However, only the first insulin input of the optimal trajectory is applied to the subject, and at the next step k + 1 the optimization process is repeated.
• MPC is based on real-time numerical optimization, and this allows for a large degree of flexibility when defining the control objective. For example, constraints can be incorporated explicitly into the optimization routine. In glycemia control, constraints on the input ensure that insulin delivery rates are constrained between prescribed minimum and maximum values.
• Zone MPC Another mechanism of exploiting the flexibility of MPC is to consider Zone MPC.
• Zone MPC for glycemia control the controller strives to maintain a blood glucose level that is within a safe zone, rather than controlling the blood glucose level to a specific set point.
• Zone MPC is applied when a specific set point value of a controlled variable (CV) is of low relevance compared to a zone that is defined by upper and lower boundaries.
• CV controlled variable
• the Zone MPC strategy of this work is implemented by defining upper and lower bounds (see Fig. S2) as soft constraints and optimizing the insulin input computation by penalizing, by means of an appropriate cost function, the deviations of predicted blood glucose levels beyond the zone.
• Fig. S2 illustrates the three zones defined in the Zone MPC, from top to bottom: Undesirably high glycemia value zone, controller target zone, and undesirably low glycemia
• the green dots in Fig. S2 indicate predicted glycemic values that are in the desired range.
• the upper zone represents undesirably high predicted glycemic values that are represented by orange dots.
• the lower zone represents undesirably low predicted glycemic values, symbolized by red dots.
• the zone below the lower bound represents either a hypoglycemic zone, or a pre-hypoglycemic protective area that is a low alarm zone.
• Zone MPC is performed employing periodically time-dependent zones, where the periodic time- dependence is with respect to the time of day. The purpose of this is to let the controller maintain safe glucose zones during the night that are different from the safe glucose zones maintained during the day, and to facilitate a smooth transition between the night and day zones. Specifically, it is desired that during the night a higher safe zone be maintained than during the day, in order to reduce the likelihood of (controller induced) hypoglycemic events during sleep. A smooth transition between night and day zones is achieved by smoothly shifting the zone boundaries according to a cosine function.
• the second of three significant changes from IDE Gl 10093 is that the online optimization of the insulin input, performed as part of the Zone MPC routine, is performed with respect to hard constraints that are periodically time-dependent.
• the periodic time- dependence is again based on the time of day.
• the upper limit of insulin input during the day is higher than the upper limit imposed during the night.
• the maximum insulin input is the maximum insulin amount deliverable by the pump, and is hardware dependent. This is the same as in the Zone MPC algorithm described in the aforementioned references.
• the maximum insulin input is a small amount higher than the basal infusion rate, and is patient dependent.
• the amount by which the upper limit is higher than a patient' s basal rate is a design parameter ( ⁇ , see Table S2).
• ⁇ see Table S2
• the purpose of having such time-dependent insulin input constraints is again to reduce the possibility of over-delivery of insulin while a patient is asleep. While appropriate choices of the safe zone definitions during the night and day should result in a controller giving near-basal insulin inputs, the night-time input constraint, enforced explicitly within the input optimization, acts as a further safety mechanism, preventing the administration of excessive insulin.
• MPC is a State-Feedback Strategy
• MPC is a state-feedback control strategy. This means that at each time step k that the controller is invoked, the controller' s internal model must be initialized to the most appropriate state, such that glucose predictions correspond as closely as possible to reality. In the case of glycemia control an appropriate state is not directly measurable. Therefore a state-estimator is employed to estimate the most appropriate state from the available blood glucose measurements.
• the state-estimator employed is a linear-estimator (sometimes referred to as a
• Luenberger-observer has a gain as a tuning parameter.
• a suitable gain can be computed, and in this supplement a change to the method of gain computation is described. This method brings the gain-computation in-line with modern system-theoretic methodologies.
• PZMPC Predictive Control
• T Z1 , T Z2 , T Z3 , and T Z4 refers to the number of minutes since midnight. Note that the time parameters must be strictly monotonically increasing, i.e.,
• T Z4 — T Z1 ⁇ 1440 min i.e., the start of nighttime must be strictly less than one day after the end of nighttime.
• C is the conversion factor and depends on the unit of the insulin infusion rate
• F s is a safety factor
• K is an individualized gain based on the correction factor using the 1800 rule:
• Table S2 is plotted in Fig. 3S.
• variable I D denotes the offset of the actual infusion rate to the basal infusion rate.
• x(k + 1) Ax(k) + BI D (k) + Le(k)
• L G R 3 denotes the estimator gain
• e(k) : y(k)— Cx(k) G R denotes the estimation error.
• the gain L must be chosen such that p(A— LC) ⁇ 1, where p() denotes the spectral radius.
• a straightforward method to determine a suitable L is by solving a Riccati equation, as follows:
• Subject 1 of the UVA Padova has the following:
• a - LC 1 0 -0.3334
• Zone MPC cost function ] ⁇ D used in the present work is defined as
• Q and R are constant optimization weights on the predicted outputs and the future proposed inputs, respectively.
• the zone-cost function is defined as follows:
• G—(k + j) if G (k + j) ⁇ G ZL (T (k + j)) (7) otherwise
• MATLAB's function 'fmincon.m' (“trust-region-reflective” algorithm) is used to solve the optimization problem (i.e., the minimization of the cost function /(/ ⁇ )) ⁇
• the following parameters are used for each optimization:
• Max_i 400, which is fixed.
• Termination tolerance Term_tol on the manipulated variables l D is 10 " .
• 24 UC2013-384PCT corresponds to gathering enough information about glucose measurements and insulin delivery rates in order to determine a reliable state estimate to initialize the prediction.
• the ratio of the output error weighting matrix (Q) and the input change weighting matrix (R) may be varied between:
• the larger Q matrix resulted in faster convergence of the state estimate.
• a useful value of Q matrix is determined to be between 1000 ⁇ / and 5000 ⁇ /.

Landscapes

• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medical Informatics (AREA)
• Biomedical Technology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Hematology (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Diabetes (AREA)
• Epidemiology (AREA)
• Primary Health Care (AREA)
• Vascular Medicine (AREA)
• Heart & Thoracic Surgery (AREA)
• Anesthesiology (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical & Material Sciences (AREA)
• Data Mining & Analysis (AREA)
• Databases & Information Systems (AREA)
• Pathology (AREA)
• Pharmacology & Pharmacy (AREA)
• Obesity (AREA)
• Endocrinology (AREA)
• Emergency Medicine (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• External Artificial Organs (AREA)
• Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
• Infusion, Injection, And Reservoir Apparatuses (AREA)
• Investigating Or Analysing Biological Materials (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=51165703

Family Applications (1)

Country Status (8)

Cited By (8)

Families Citing this family (70)

Citations (5)

Family Cites Families (8)

• 2014
  • 2014-01-14 EP EP14738072.9A patent/EP2943150B1/en active Active
  • 2014-01-14 CA CA2897925A patent/CA2897925C/en active Active
  • 2014-01-14 US US14/154,241 patent/US10507284B2/en active Active
  • 2014-01-14 JP JP2015552873A patent/JP6810989B2/ja active Active
  • 2014-01-14 CN CN201480015278.4A patent/CN105050539B/zh active Active
  • 2014-01-14 WO PCT/US2014/011378 patent/WO2014110541A1/en not_active Ceased
  • 2014-01-14 AU AU2014205123A patent/AU2014205123B2/en active Active
  • 2014-01-14 KR KR1020157021677A patent/KR102212020B1/ko active Active

Patent Citations (5)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events